Interacciones de Glucagón

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists, including BYETTA [see Adverse Reactions (6.2) ] . (etiqueta de Exenatida, Advertencias y precauciones)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (etiqueta de Glucagón, Interacciones medicamentosas)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (etiqueta de Glucagón, Interacciones medicamentosas)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure. (etiqueta de Glucagón, Advertencias y precauciones)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (etiqueta de Glucagón, Interacciones medicamentosas)

The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics,… (etiqueta de Glimepirida, Interacciones medicamentosas)

…glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (etiqueta de Glipizida, Interacciones medicamentosas)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (etiqueta de Glucagón, Interacciones medicamentosas)

Indomethacin Clincial Impact: In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. (etiqueta de Glucagón, Interacciones medicamentosas)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (etiqueta de Glucagón, Advertencias y precauciones)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (etiqueta de Glucagón, Advertencias y precauciones)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (etiqueta de Glucagón, Advertencias y precauciones)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (etiqueta de Glucagón, Advertencias y precauciones)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (etiqueta de Glucagón, Advertencias y precauciones)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (etiqueta de Glucagón, Advertencias y precauciones)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Hyperglycemia and Hypoglycemia Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. (etiqueta de Lanreotida, Advertencias y precauciones)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Hyperglycemia and Hypoglycemia MYCAPSSA alters the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone, which may result in hypoglycemia, or hyperglycemia, or diabetes mellitus. (etiqueta de Octreotida, Advertencias y precauciones)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics,… (etiqueta de Pioglitazona y glimepirida, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (etiqueta de Glucagón, Interacciones medicamentosas)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (etiqueta de Glucagón, Advertencias y precauciones)

Intervention Monitor patients for unusual bruising or bleeding, as adjustments in warfarin dosage may be required. (etiqueta de Glucagón, Interacciones medicamentosas)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

Glucagon-like peptide-1 (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures. (etiqueta de Dulaglutida, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (etiqueta de Repaglinida, Interacciones medicamentosas)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)